On July 29, 2020 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, reported it will provide an update on programs and plans and release its second quarter 2020 financial results before the market opens on Thursday, August 6, 2020 (Press release, Agenus, JUL 29, 2020, View Source [SID1234562506]). Agenus executives and thought leaders will host a video conference call and webcast at 8:30 a.m. ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Topics to be discussed:
Registration plans and strategy for balstilimab +/- zalifrelimab
Agenus & Betta Pharmaceuticals partnership progress for China
Clinical status/next steps for AGEN1181 (NextGen CTLA-4) +/- balstilimab (anti-PD-1)
Allogeneic iNKT cells potential breakthrough for COVID-19 and cancer based on efficacy and cost
Cell therapy and antibody combinations preclinically show curative potential
AGEN1223 & AGEN2373 clinical update and plans for bali +/- zali combos
Myeloid immune response modifiers (TIGIT bispecific & other novel targets)
Live Call: Dial 1-844-492-3727 (U.S.) or 1-412-317-5118 (International)
Webcast: The call will be accessible from the Company’s website at View Source or via View Source A replay will be available approximately two hours after the call and will remain available until November 7, 2020.